<DOC>
	<DOCNO>NCT01562197</DOCNO>
	<brief_summary>This clinical trial recruit patient diagnose glioblastoma time recurrence progression follow prior treatment surgery , radiation therapy alkylating chemotherapy . Patients screen found eligible randomized one two treatment arm ( 1:1 randomization ) . Patients randomized Axitinib treatment-arm treat Axitinib progression ( treated progression Axitinib plus lomustine arm ) , unacceptable treatment related toxicity , patient refusal continue study treatment . Patients randomize Axitinib plus Lomustine-arm receive treatment progression , unacceptable treatment related toxicity , patient refusal continue study treatment .</brief_summary>
	<brief_title>A Randomized Phase II Clinical Trial Efficacy Axitinib Monotherapy Combination With Lomustine Treatment Patients With Recurrent Glioblastoma</brief_title>
	<detailed_description />
	<mesh_term>Glioblastoma</mesh_term>
	<mesh_term>Axitinib</mesh_term>
	<mesh_term>Lomustine</mesh_term>
	<criteria>1 . Histopathological diagnosis glioblastoma ( = WHO grade IV glioma central nervous system ) ; `` de novo '' `` secondary '' glioblastoma eligible ; 2 . Diagnosis glioma recurrence progression follow prior treatment surgery , radiation therapy alkylating chemotherapy ( define significant [ accord investigator individual assessment ] growth recurrence glioblastoma demonstrate sequential GdMRI time recruitment ) . 3 . The following disease characteristic present : 1 . Presence measurable tumor lesion characterize gadolinium enhancement T1MRI brain ( long diameter &gt; 10 mm ) ; 2 . Enhancing characteristic glioblastoma compare normal brain 18FFET PET ( patient nonenhancing lesion eligible ) ; 3 . No evidence clinically meaningful spontaneous intratumoral hemorrhage baseline MRIimaging prior disease history ; 4 . No contraindication evaluation GdMRI 18FFET PET brain ; 5 . Archival glioma tissue must available collection storage centralize tumor bank ; 6 . An interval least 3 month ( 12 week ) end prior radiation therapy ; interval least 4 week last administration cytotoxic drug treatment ( 6 week case administration nitrosureum mitomycin C ) ; interval least 4 week last administration kind anti glioblastoma treatment ; 7 . A stable dose corticosteroid least 14 day initiation study treatment axitinib ; 8. WHO performance status 0 1 ; 9 . Life expectancy ≥12 week ; 10 . Male female , 18 year age old ; 11 . Resolution acute toxic effect prior systemic therapy , radiotherapy surgical procedure NCI CTCAEv3.0 grade 0 1 back baseline except alopecia hypothyroidism ; 12 . Adequate organ function define follow criterion : Total serum bilirubin &lt; 1.5 x ULN ( patient Gilbert 's disease exempt ) AST ALT &lt; 2.5 x upper limit normal ( ULN ) ; Serum creatinine ≤1.5 x ULN calculate creatinine clearance ≥60 mL/min Absolute neutrophil count ( ANC ) &gt; 1500/mm³ without growth factor support Platelets &gt; 75 000 cells/mm³ Hemoglobin ≥9 g/dL ( may obtain transfusion growth factor support ) Urinary protein &lt; 1+ urine dipstick . If dipstick ≥1+ 24hour urine collection do patient may enter urinary protein &lt; 2 gram per 24 hour 13 . Women childbearing potential must negative serum urine pregnancy test within 3 day prior treatment . ; 14 . Female patient must surgically sterile postmenopausal , must agree use effective contraception measure period therapy continue 4 week last dose axitinib . All female patient reproductive potential must negative pregnancy test ( serum urine ) prior enrollment . Male patient must surgically sterile must agree use effective contraception period therapy . The definition effective contraception base judgment principal investigator designate associate ; 15 . No previous treatment axitinib trial ; 16 . No previous treatment VEGF VEGFRtargeted drug ( include , limited bevacizumab , aflibercept , cediranib , sorafenib , sunitinib , XL184 , pazopanib ) ; 17 . No gastrointestinal abnormality include : 1 . Inability take oral medication . 2 . Requirement intravenous alimentation . 3 . Prior surgical procedure affect absorption include gastric resection . 4 . Treatment active peptic ulcer disease past 6 month . 5 . Malabsorption syndrome . 6 . Active gastrointestinal bleeding , unrelated cancer , evidence hematemesis , hematochezia melena past 3 month without evidence resolution document endoscopy colonoscopy ; 18 . No evidence preexist uncontrolled hypertension document 2 baseline blood pressure read take least 1 hour apart . The baseline systolic blood pressure reading must ≤140 mm Hg , baseline diastolic blood pressure reading must ≤90 mm Hg . Patients whose hypertension control antihypertensive therapy eligible ; 19 . No concurrent treatment : 1 . In another therapeutic clinical trial ; 2 . With drug proarrhythmic potential ; 3 . With enzyme induce antiepileptic drug ( EIAED ) within 14 day dose axitinib ( e.g . carbamazepine , phenobarbital , phenytoin ) ; 20 . No current use anticipate need treatment drug know potent CYP3A4 inhibitor ( ie , grapefruit juice , verapamil , ketoconazole , miconazole , itraconazole , erythromycin , telithromycin , clarithromycin , indinavir , saquinavir , ritonavir , nelfinavir , lopinavir , atazanavir , amprenavir , fosamprenavir delavirdine ) . 21 . No current use anticipate need treatment drug know CYP3A4 CYP1A2 inducer ( ie , carbamazepine , dexamethasone , felbamate , omeprazole , phenobarbital , phenytoin , amobarbital , nevirapine , primidone , rifabutin , rifampin , St. John 's wort ) . 22 . No requirement anticoagulant therapy oral vitamin K antagonists . Lowdose anticoagulant maintenance patency central venous access devise prevention deep venous thrombosis allow . Therapeutic use low molecular weight heparin allow . 23 . No active seizure disorder evidence brain metastasis , spinal cord compression , carcinomatous meningitis . 24 . No myocardial infarction , severe/unstable angina , coronary/peripheral artery bypass graft , symptomatic congestive heart failure unstable arrhythmia , cerebrovascular accident transient ischemic attack , within 12 month prior study drug administration . No current recent ( within 1 month ) use thrombolytic agent thromboembolic event ; 25 . No known human immunodeficiency virus ( HIV ) acquire immunodeficiency syndrome ( AIDS ) relate illness ; 26 . No serious uncontrolled medical disorder active infection would impair ability receive study treatment ; 27 . No history malignancy ( glioma ) except treat curative intent skin cancer ( melanoma ) situ breast cervical cancer treat curative intent cancer evidence disease 5 year ; 28 . No major surgical procedure , open biopsy , significant traumatic injury within 4 week treatment . ( Also exclude patient fine needle aspiration within 7 day treatment ) ; 29 . No pregnancy breastfeed ; 30 . No history hemoptysis &gt; ½ tsp bright red blood per day within past 1 week ; 31 . No severe acute chronic medical psychiatric condition , laboratory abnormality would impart , judgment investigator , excess risk associate study participation study drug administration , , judgment investigator , would make patient inappropriate entry study ; 32 . No dementia significantly alter mental status would prohibit understanding rendering informed consent compliance requirement protocol ; 33 . Signed date informed consent document indicate patient ( legally acceptable representative ) inform pertinent aspect trial prior enrollment ; 34 . Willingness ability comply schedule visit , treatment plan laboratory test study procedure .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>axitinib</keyword>
	<keyword>glioblastoma</keyword>
	<keyword>recurrent</keyword>
</DOC>